EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evolution of seroprevalence to SARS‐CoV‐2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross‐sectional and longitudinal studies

Sanjin Musa iD, Elma Catovic Baralija, Veronica Ivey Sawin, Anthony Nardone, Mirza Palo, Sinisa Skocibusic, Mia Blazevic, Seila Cilovic Lagarija, Gorana Ahmetovic-Karic, Alma Ljuca, Sanela Dostovic-Halilovic, Rozalija Nedic und 6 weitere

Influenza and Other Respiratory Viruses · 2023

DOI: 10.1111/irv.13182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, 2023. Verfasst von Sanjin Musa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Public Health of the Federation of Bosnia and Herzegovina Sarajevo Bosnia and Herzegovina. Hauptthemen laut MEDLINE: Blood Donors, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sarajevo Canton in the Federation of Bosnia and Herzegovina has recorded several waves of high SARS‐CoV‐2 transmission and has struggled to reach adequate vaccination coverage. We describe the evolution of infection‐ and vaccine‐induced SARS‐CoV‐2 antibody response and persistence.

Methods

We conducted repeated cross‐sectional analyses of blood donors aged 18–65 years in Sarajevo Canton in November–December 2020 and 2021. We analyzed serum samples for anti‐nucleocapsid (anti‐N) and anti‐spike (anti‐S) antibodies. To assess immune durability, we conducted longitudinal analyses of seropositive participants at 6 and 12 months.

Results

One thousand fifteen participants were included in Phase 1 (November–December 2020) and 1152 in Phase 2 (November–December 2021). Seroprevalence increased significantly from 19.2% (95% CI: 17.2%–21.4%) in Phase 1 to 91.6% (95% CI: 89.8%–93.1%) in Phase 2. Anti‐S IgG titers were significantly higher among vaccinated (58.5%) than unvaccinated infected participants across vaccine products ( p < 0.001), though highest among those who received an mRNA vaccine. At 6 months, 78/82 (95.1%) participants maintained anti‐spike seropositivity; at 12 months, 58/58 (100.0%) participants were seropositive, and 33 (56.9%) had completed the primary vaccine series within 6 months. Among 11 unvaccinated participants who were not re‐infected at 12 months, anti‐S IgG declined from median 770.1 (IQR 615.0–1321.7) to 290.8 (IQR 175.7–400.3). Anti‐N IgG antibodies waned earlier, from 35.4% seropositive at 6 months to 24.1% at 12 months.

Conclusions

SARS‐CoV‐2 seroprevalence increased significantly over 12 months from end of 2020 to end of 2021. Although individuals with previous infection may have residual protection, COVID‐19 vaccination is vital to strengthening population immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood DonorsCOVID-19HumansBosnia and HerzegovinaCOVID-19 VaccinesCross-Sectional StudiesSARS-CoV-2Seroepidemiologic StudiesLongitudinal StudiesImmunoglobulin G

Stichwörter der Autor:innen

Bosnia and HerzegovinaSARS‐CoV‐2cross‐sectional studylongitudinal studyseroprevalence

Substanzen

COVID-19 VaccinesImmunoglobulin G

Autor:innen und Institutionen

  • Institute for Public Health of the Federation of Bosnia and Herzegovina Sarajevo Bosnia and Herzegovina.
  • Sarajevo School of Science and Technology Sarajevo Medical School Sarajevo Bosnia and Herzegovina.
  • Institute for Transfusion Medicine of the Federation of Bosnia and Herzegovina Sarajevo Bosnia and Herzegovina.
  • Epiconcept Paris France.
  • World Health Organization Office in Bosnia and Herzegovina Sarajevo Bosnia and Herzegovina.
  • World Health Organization Geneva Switzerland.

ORCID-Profile: Sanjin Musa, Isabel Bergeri

Förderung

  • World Health Organization

Zitieren

APA

Musa, S., Catovic Baralija, E., Ivey Sawin, V., Nardone, A., Palo, M., Skocibusic, S., Blazevic, M., Cilovic Lagarija, S., Ahmetovic-Karic, G., Ljuca, A., Dostovic-Halilovic, S., Nedic, R., Subissi, L., Ibrahim, R., Boshevska, G., Bergeri, I., Pebody, R., & Vaughan, A. (2023). Evolution of seroprevalence to SARS‐CoV‐2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross‐sectional and longitudinal studies. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13182

Vancouver

Musa S, Catovic Baralija E, Ivey Sawin V, Nardone A, Palo M, Skocibusic S, et al. Evolution of seroprevalence to SARS‐CoV‐2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross‐sectional and longitudinal studies. Influenza and Other Respiratory Viruses. 2023. doi:10.1111/irv.13182

BibTeX
@article{Musa2023,
  author = {Musa, Sanjin and Catovic Baralija, Elma and Ivey Sawin, Veronica and Nardone, Anthony and Palo, Mirza and Skocibusic, Sinisa and Blazevic, Mia and Cilovic Lagarija, Seila and Ahmetovic-Karic, Gorana and Ljuca, Alma and Dostovic-Halilovic, Sanela and Nedic, Rozalija and Subissi, Lorenzo and Ibrahim, Rawi and Boshevska, Golubinka and Bergeri, Isabel and Pebody, Richard and Vaughan, Aisling},
  title = {Evolution of seroprevalence to SARS‐CoV‐2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross‐sectional and longitudinal studies},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2023},
  doi = {10.1111/irv.13182}
}
Kostenlos starten →